Ipamorelin vs CJC-1295+Ipamorelin Blend
Ipamorelin is one of the two components inside the CJC-1295+Ipamorelin Blend, so this comparison contrasts single-compound sourcing with a fixed-ratio blend. The individual Ipamorelin vial (10 mg) allows independent dose control for growth-hormone-secretagogue research. The blend vial (10 mg total) provides Ipamorelin alongside CJC-1295 No DAC at a fixed 1:1 ratio. The choice depends on protocol-design requirements.
Side-by-side comparison
| Property | Compound A | Compound B |
|---|---|---|
| Format | Single compound (10 mg Ipamorelin) | Two-compound blend (CJC-1295 No DAC 5 mg + Ipamorelin 5 mg) |
| Dose control | Independent: researcher sets Ipamorelin dose without constraint | Fixed 1:1 ratio: adjusting one compound changes the other proportionally |
| Receptor targets | Ghrelin receptor (GHS-R1a) selective secretagogue | Ghrelin receptor (Ipamorelin) + GHRH receptor (CJC-1295 No DAC) |
| GH-release mechanism | Pulsatile GH release via ghrelin-receptor engagement | Dual-axis: pulsatile GH release (Ipamorelin) + amplified GH pulse amplitude (CJC-1295 No DAC) |
| Total vial mass | 10 mg | 10 mg |
| Reconstitution | Bacteriostatic water; lyophilised vial | Bacteriostatic water; lyophilised vial |
| Ronin catalog format | Single-compound lyophilised vial | Lyophilised blend vial |
How they differ in mechanism
Ipamorelin as a standalone compound engages the ghrelin receptor (GHS-R1a) as a selective growth-hormone secretagogue. The published literature describes it as selective for GH release without significant effects on ACTH, cortisol, or prolactin at GH-stimulating doses. The Raun et al. characterisation identified it as the first selective GH secretagogue. The standalone vial allows the researcher to set Ipamorelin dose independently.
The CJC-1295+Ipamorelin Blend combines Ipamorelin (5 mg) with CJC-1295 No DAC (5 mg), a GHRH analogue that engages the growth-hormone-releasing-hormone receptor on anterior pituitary somatotrophs. The combination engages two complementary axes of GH regulation: Ipamorelin provides the ghrelin-receptor stimulus for pulsatile GH release, and CJC-1295 provides the GHRH-receptor stimulus that amplifies GH pulse amplitude.
The dual-receptor engagement is the rationale for the blend. The standalone Ipamorelin vial provides one axis (ghrelin receptor). The blend provides both axes at a fixed 1:1 ratio. Whether the dual-axis approach serves a given research question depends on the protocol design.
How research has examined each
The Ipamorelin literature includes the initial selectivity characterisation (Raun et al., 1998), postoperative ileus models (Venkova et al., 2009; Beck et al., 2014), and pharmacokinetic evaluation (Johansen et al., 1998). The compound is distinguished by its selectivity for GH release relative to other GH secretagogues.
The CJC-1295 (No DAC) literature centres on GHRH-receptor engagement, GH and IGF-1 axis activation (Teichman et al., 2006; Alba et al., 2006), and pulsatile-secretion preservation (Ionescu et al., 2006). No published study examines the specific CJC-1295 + Ipamorelin combination at the blend ratio.
The dual-axis concept (ghrelin receptor + GHRH receptor) is pharmacologically grounded in the complementary GH-release pathways, but the specific combination at the 1:1 mass ratio is a sourcing format rather than a published protocol replication.
Stacking considerations in research contexts
Adding standalone Ipamorelin to a CJC-1295+Ipamorelin Blend protocol would increase total Ipamorelin dose while maintaining the fixed CJC-1295 contribution. This shifts the axis balance toward more ghrelin-receptor stimulus relative to GHRH-receptor stimulus. Researchers typically select one sourcing format.
Sourcing both at Ronin
The Ipamorelin vial page provides 10 mg as a single compound. The CJC-1295+Ipamorelin Blend page provides 10 mg total of the two-compound blend. Both ship as lyophilised peptide in glass vials with certificate-of-analysis documentation. Both are research-grade reagents.
Both compounds are also available together in the combined-formulation vial for researchers using the canonical fixed-ratio combination.
Frequently asked research questions
Is the Ipamorelin identical in both formats?
Yes. The Ipamorelin peptide is the same selective GH secretagogue. The difference is mass (10 mg standalone versus 5 mg within the blend) and whether CJC-1295 No DAC is co-formulated.
What does CJC-1295 add?
CJC-1295 No DAC engages the GHRH receptor on pituitary somatotrophs. Combined with Ipamorelin’s ghrelin-receptor engagement, the blend provides dual-axis GH-release stimulation.
Why choose the standalone Ipamorelin?
Independent dose control and the option to combine with CJC-1295 or other compounds at researcher-determined ratios.
Has the combination been studied?
No published study examines Ipamorelin + CJC-1295 at the blend ratio. Both have independent research literatures.
Are either approved for human use?
Neither is approved by the FDA or Health Canada. Both are research-grade reagents.
References
- Raun K et al. Ipamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology, 1998. [PMID 9849822]
- Teichman SL et al. Prolonged stimulation of growth hormone and IGF-I secretion by CJC-1295. Journal of Clinical Endocrinology and Metabolism, 2006. [PMID 16352683]
- Alba M et al. Once-daily administration of CJC-1295 normalizes growth in the GHRH knockout mouse. American Journal of Physiology, 2006. [PMID 16822960]
- Venkova K et al. Efficacy of ipamorelin in a rodent model of postoperative ileus. Journal of Pharmacology and Experimental Therapeutics, 2009. [PMID 19289567]
- Beck DE et al. Proof-of-concept study of ipamorelin for postoperative ileus in bowel resection patients. International Journal of Colorectal Disease, 2014. [PMID 25331030]
Comparison pages describe research-context use of the compared compounds. They do not constitute medical, veterinary, or clinical advice. Every compound in the Ronin catalog is sold strictly for laboratory and research use only.